Market Size in 2022 | Market Forecast in 2030 | Growth Rate (in %) | Base Year |
---|---|---|---|
USD 4.31 Billion | USD 85.61 Billion | CAGR at 45.31% | 2022 |
According to the report published by Zion Market Research, the global T-Cell Therapies Market size was valued at USD 4.31 Billion in 2022 and is predicted to reach USD 85.61 Billion by the end of 2030. The market is expected to grow with a CAGR of 45.31% during the forecast period. The report analyzes the global T-Cell Therapies Market’s growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the T-Cell Therapies Market industry.
CAR-T cell therapy is used to effectively treat patients with blood cancer. It is the most effective technique available for treating patients who have already undergone through other treatments like chemotherapy. CAR-T cell therapy consists of reengineered white blood cells to fight cancer cells. The process involves the extraction of T-cells of the patients and then reformed to place them again inside the body of patients so that the reformed cells can multiply and efficiently attack the cancer cells.
One of the major factors driving the global T-cell therapies market is the growing incidences of cancer patients across the globe. Moreover, the increasing technological advancements in therapies to treat and diagnose cancer in the earlier stages of cancer so that proper treatments can be facilitated to the patients also propel the market growth. The emerging gene therapy system is playing an important role in the growth of T-cell therapies. The growing investments in gene therapy are likely to boost the growth of the global T-cell therapies market. The growing concentration of companies to develop off-shelf allogeneic CAR-T therapies for better treatment of patients is also propelling the market growth globally. The rising investments by major market payers to develop and remodel CAR-T therapies to lower the adverse effects of the treatments on cancer patients is supporting the global market significantly. The emergence of next-generation CAR-T cells coupled with the artificial intelligence and machine learning concepts in the market further contributes to development of the CAR-T therapies.
The global T-cell therapies market can be segmented into modality, indication, therapy type, and region.
By modality, the market can be segmented into commercialized and research.
By indication, the market can be segmented into solid tumors, hematologic malignancies, and others. The hematologic malignancies segment dominates the global T-cell therapies market due to the growing number of market entrants and the fixed price of autologous cell manufacturing. It can further be segmented into myeloma, leukemia, and lymphoma. The solid tumors segment can further be segmented into liver cancer, brain & central nervous system, melanoma, and others.
By therapy type, the market can be segmented into tumor-infiltrating lymphocytes (TIL)-based, T cell receptor (TCR)-based, and CAR T-cell therapy. The CAR T-cell therapy accounts for the largest share in the global T-cell therapies market owing to the growing technological advancements in CAR-T therapy. Moreover, the adoption of approaches like next-generation CAR-T immunotherapy and second-generation to overcome the underlying challenges is fueling the growth of the segment.
Report Attributes | Report Details |
---|---|
Report Name | T-Cell Therapies Market Research Report |
Market Size in 2022 | USD 4.31 Billion |
Market Forecast in 2030 | USD 85.61 Billion |
Growth Rate | CAGR of 45.31% |
Number of Pages | 180 |
Key Companies Covered | Johnson & Johnson, Sorrento Therapeutics, Fate Therapeutics, Inc., Eli Lilly and Company, Juno Therapeutics, Amgen, Inc., Celgene Corporation, Pfizer Inc., Sorrento Therapeutics, Bluebird Bio Inc., TCR2 Therapeutics Inc, Gilead Sciences Inc., Merck KGaA, Immatics, GammaDelta Therapeutics, Crescendo Biologics, Celyad, Cellectis, BioNTech, Autolus Therapeutics, Astellas Pharma, AstraZeneca Holding GmbH, MSD Laboratories India LLC, Hebei Senlang Biotech, PersonGen Biomedicine, Innovative Cellular Therapeutics Cellular Biomedicine Group, Takeda Pharmaceutical Company, Nipro Corporation, Japan Tissue Engineering, Ono Pharmaceutical, Otsuka Pharmaceutical, Gracell Biotechnology Ltd, and Novartis AG. |
Segments Covered | By Modality, By Indication, By Therapy Type By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2023 - 2030 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America holds the largest share in the global T-cell therapies market due to the growing research and development activities in the region. Moreover, the presence of a strong commercial base in the region coupled with a growing number of successful clinical trials for T cell therapy also propels the regional market growth.
Asia Pacific is expected to witness huge growth with high CAGR during the forecast period due to the increasing number of medical centers facilitating the CAR-T cell therapies. The emergence of prominent market players in the global T-cell therapies market also boosts the regional market growth.
Some of the significant players in the global T-cell therapies market are:
The global T-Cell Therapies Market is segmented as follows:
By Modality
By Indication
By Therapy Type
FrequentlyAsked Questions
One of the major factors driving the global T-cell therapies market is the growing incidences of cancer patients across the globe. Moreover, the increasing technological advancements in therapies to treat and diagnose cancer in the earlier stages of cancer so that proper treatments can be facilitated to the patients also propel the market growth.
Some of the significant players in the global T-cell therapies market are Johnson & Johnson, Sorrento Therapeutics, Fate Therapeutics, Inc., Eli Lilly and Company, Juno Therapeutics, Amgen, Inc., Celgene Corporation, Pfizer Inc
North America holds the largest share in the global T-cell therapies market due to the growing research and development activities in the region. Moreover, the presence of a strong commercial base in the region coupled with a growing number of successful clinical trials for T cell therapy also propels the regional market growth.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed